Korro Bio Advances KRRO-111 as Potential Best-in-Class AATD Therapy

Event summary

  • Korro Bio selected KRRO-111 as its development candidate for Alpha-1 Antitrypsin Deficiency (AATD) on May 19, 2026.
  • Preclinical data showed >90% editing of SERPINA1 transcript in vivo, translating to ~90% repaired functional AAT protein in plasma in a mouse model.
  • KRRO-111 demonstrated near elimination of active Z-protein production and progressive clearance of pre-existing aggregates in a mouse model.
  • The company plans to present additional data from its KRRO-111 program at a future scientific meeting or company-hosted event.

The big picture

Korro Bio's selection of KRRO-111 as a development candidate for AATD highlights the potential of its OPERA platform to deliver precise, tissue-directed RNA editing. This advancement comes at a time when the biopharmaceutical industry is increasingly focused on genetic medicines for rare diseases, offering a more targeted and potentially safer alternative to traditional therapies. The company's ability to leverage its platform for multiple indications, including hyperammonemia, positions it as a key player in the genetic medicine space.

What we're watching

Clinical Translation
How KRRO-111's preclinical efficacy will translate into clinical settings and whether it can achieve the functional equivalent of a DNA modification without altering the genome.
Market Differentiation
Whether KRRO-111 can position itself as a best-in-class therapy in a market currently dominated by augmentation therapy.
Pipeline Progression
The pace at which Korro Bio can advance both KRRO-111 and KRRO-121 through clinical trials, given its current capitalization.